In vivo confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-L-aspartylchlorin-e6.
暂无分享,去创建一个
[1] Jarod C Finlay,et al. Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. , 2005, Journal of photochemistry and photobiology. B, Biology.
[2] Barbara W. Henderson,et al. Choice of Oxygen-Conserving Treatment Regimen Determines the Inflammatory Response and Outcome of Photodynamic Therapy of Tumors , 2004, Cancer Research.
[3] J. Usuda,et al. Photodynamic therapy (PDT) for lung cancers. , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] Tayyaba Hasan,et al. Tumor Vascular Permeabilization by Vascular-Targeting Photosensitization: Effects, Mechanism, and Therapeutic Implications , 2006, Clinical Cancer Research.
[5] Thomas H Foster,et al. Photophysical Parameters, Photosensitizer Retention and Tissue Optical Properties Completely Account for the Higher Photodynamic Efficacy of meso-Tetra-Hydroxyphenyl-Chlorin vs Photofrin¶ , 2005, Photochemistry and photobiology.
[6] D. Kessel,et al. Pharmacokinetics of N-aspartyl chlorin e6 in cancer patients. , 1997, Journal of photochemistry and photobiology. B, Biology.
[7] D. Kessel,et al. Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398. , 2005, American journal of surgery.
[8] Effects of photodynamic therapy using a fractionated dosing of mono-L-aspartyl chlorin e6 in a murine tumor. , 2005, Journal of photochemistry and photobiology. B, Biology.
[9] P. H. Moore,et al. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response. , 1994, Cancer research.
[10] T. Wieman,et al. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[11] Barbara W Henderson,et al. Photodynamic therapy: a means to enhanced drug delivery to tumors. , 2003, Cancer research.
[12] D. Kessel. Correlation between subcellular localization and photodynamic efficacy , 2004 .
[13] T. Foster,et al. Confocal fluorescence spectroscopy and anisotropy imaging system. , 2003, Optics letters.
[14] M. Trotter,et al. The use of fluorescent probes to identify regions of transient perfusion in murine tumors. , 1989, International journal of radiation oncology, biology, physics.
[15] T. Albertson,et al. Pharmacokinetics and clinical effects of mono‐l‐aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces , 2005, Photodermatology, photoimmunology & photomedicine.
[16] T. Vogl,et al. A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors , 2003, Cancer.
[17] M. Biel,et al. mTHPC‐mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients , 2004, Head & neck.
[18] Lina Bolotine,et al. Temporally and Spatially Heterogeneous Distribution of mTHPC in a Murine Tumor Observed by Two-color Confocal Fluorescence Imaging and Spectroscopy in a Whole-mount Model , 2005, Photochemistry and photobiology.
[19] C J Gomer,et al. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model. , 1990, Cancer research.
[20] P B Cerrito,et al. The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. , 1992, Cancer research.
[21] Michael R Hamblin,et al. In vivo fluorescence imaging of the transport of charged chlorine6 conjugates in a rat orthotopic prostate tumour , 1999, British Journal of Cancer.
[22] B. Pogue,et al. Analysis of Effective Molecular Diffusion Rates for Verteporfin in Subcutaneous Versus Orthotopic Dunning Prostate Tumors¶ , 2004, Photochemistry and photobiology.
[23] T. Foster,et al. Photofrin and light induces microtubule depolymerization in cultured human endothelial cells. , 1992, Cancer research.
[24] R. Jain. The next frontier of molecular medicine: Delivery of therapeutics , 1998, Nature Medicine.
[25] C. Hadjur,et al. Photodynamic therapy of early squamous cell carcinoma with tetra(m-hydroxyphenyl)chlorin: optimal drug-light interval. , 1997, British Journal of Cancer.
[26] Arjun G. Yodh,et al. Noninvasive Monitoring of Murine Tumor Blood Flow During and After Photodynamic Therapy Provides Early Assessment of Therapeutic Efficacy , 2005, Clinical Cancer Research.
[27] C J Gomer,et al. Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model. , 1992, Cancer research.
[28] J. Kennedy,et al. A recipe for the preparation of a rodent food that eliminates chlorophyll-based tissue fluorescence. , 1995, Journal of photochemistry and photobiology. B, Biology.
[29] Ken Kang-Hsin Wang,et al. A comprehensive mathematical model of microscopic dose deposition in photodynamic therapy. , 2006, Medical physics.